Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Immunoblastic Lymphadenopathy 3Burkitt Lymphoma 3Melanoma 2Hodgkin Disease 2Breast Neoplasms 2Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Intraocular Lymphoma 1

Interventions

tanespimycin 1pemigatinib 1pembrolizumab 1MLN8054 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Malignancies × tanespimycin × Clear all
NCT00724425 2015-04-15

A Phase 1 Dose Escalation Study of IPI-493

Infinity Pharmaceuticals, Inc.

Phase 1 Terminated
53 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡